Catalyst Event

Sino Biopharmaceutical Ltd (1177) · Other

From Akros SCHK HK-U.S. Biotech Index (ASHUBIO)

6/4/2026, 12:00:00 AM

OtherSentiment: Positive

The company presented positive Phase III trial data for its 'Defu Combination' (Anlotinib plus Bemotuzumab) as a first-line treatment for non-squamous non-small cell lung cancer (nsq-NSCLC) at the 2026 ASCO meeting, showing a significant 6-month improvement in median Progression-Free Survival (mPFS) compared to the control group.

Korean Translation

2026년 미국임상종양학회(ASCO)에서 비편평 비소세포폐암(nsq-NSCLC) 1차 치료제로서 '더푸 콤비네이션'(안로티닙+베모투주맙)의 긍정적인 3상 임상 데이터를 발표했으며, 대조군 대비 무진행 생존기간 중앙값(mPFS)이 6개월 유의미하게 개선되었음을 보임.

Related Recent Events

View Full Timeline